3-methyl-3-aza-bicyclo[3.2.0]heptane | 90048-85-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环庚烷
• 英文名称: 3-methyl-3-aza-bicyclo[3.2.0]heptane
• 英文别名: 3-Methyl-3-aza-bicyclo[3.2.0]heptan；N-Methyl-3-azabicyclo<3.2.0>heptan；3-Methyl-3-azabicyclo[3.2.0]heptane
• CAS: 90048-85-4
• 化学式: C₇H₁₃N
• 分子量: 111.187
• InChiKey: RGOQOMIRSBZPMD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-methyl-3-aza-bicyclo[3.2.0]heptane 、 碘甲烷 在 异丙醇 作用下， 生成 3,3-dimethyl-3-azonia-bicyclo[3.2.0]heptane
  参考文献：
  名称：

  Hypotensive Agents. VII.¹ Azabicyclo[3.2.0]heptane Derivatives²

  摘要：

  DOI：

  10.1021/jo01360a029
• 作为产物：
  描述：

  3-methyl-3-aza-bicyclo[3.2.0]heptane-2,4-dione 在 lithium aluminium tetrahydride 、 乙醚 作用下， 生成 3-methyl-3-aza-bicyclo[3.2.0]heptane
  参考文献：
  名称：

  Hypotensive Agents. VII.¹ Azabicyclo[3.2.0]heptane Derivatives²

  摘要：

  DOI：

  10.1021/jo01360a029

文献信息

• Heteroaromatic Carboxamide Derivatives as Plasma Kallikrein Inhibitors
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20200054617A1

  公开（公告）日：2020-02-20

  Heteroaromatic carboxamides of formula (I), wherein Y, R, and X are as defined herein, and pharmaceutically acceptable salts thereof. The compounds of formula (I) can be used in methods for the treatment of diseases which can be influenced by inhibition of plasma kallikrein.

  式(I)的杂环芳基羧酰胺，其中Y、R和X如本文所定义，并其药学上可接受的盐。式(I)的化合物可用于治疗受血浆激肽酶抑制影响的疾病的方法。
• [EN] HETEROARYL COMPOUNDS AND PHARMACEUTICAL APPLICATIONS THEREOF<br/>[FR] COMPOSÉS HÉTÉROARYLES ET LEURS APPLICATIONS PHARMACEUTIQUES
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2016000615A1

  公开（公告）日：2016-01-07

  The present invention provides herein is a heteroaryl compound or a stereoisomer, a geometric isomer, a tautomer, a racemate, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, as well as a pharmaceutical composition containing the compound disclosed herein. The present invention also provides herein is use of the compound or the pharmaceutical composition thereof disclosed herein in the manufacture of a medicine for treating autoimmune diseases or proliferative diseases.

  本发明提供的是一种杂环芳基化合物或其立体异构体、几何异构体、互变异构体、消旋体、N-氧化物、水合物、溶剂合物、代谢物、药学上可接受的盐或其前药，以及含有本文所披露的化合物的药物组合物。本发明还提供的是使用本文所披露的化合物或其药物组合物制造用于治疗自身免疫疾病或增殖性疾病的药物。
• N-SUBSTITUTED AMINOBENZOCYCLOHEPTENE, AMINOTETRALINE, AMINOINDANE AND PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY
  申请人：AbbVie Deutschland GmbH & Co. KG

  公开号：US20130131132A1

  公开（公告）日：2013-05-23

  The present invention relates to N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives of the formula (I), (II), (III) or (IV) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, and the use of such N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives for therapeutic purposes. The N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives are GlyT1 inhibitors.

  本发明涉及式(I)、(II)、(III)或(IV)所示的N-取代氨基苯并环庚烯、氨基四氢异喹啉、氨基吲哚和苯基烷基胺衍生物 或其生理耐受盐。 该发明涉及包含上述N-取代氨基苯并环庚烯、氨基四氢异喹啉、氨基吲哚和苯基烷基胺衍生物的药物组合物，以及将上述N-取代氨基苯并环庚烯、氨基四氢异喹啉、氨基吲哚和苯基烷基胺衍生物用于治疗用途。所述N-取代氨基苯并环庚烯、氨基四氢异喹啉、氨基吲哚和苯基烷基胺衍生物是甘氨酸转运体1抑制剂。
• [EN] HETEROCYCLIC ESTROGEN RECEPTOR MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DES RÉCEPTEURS D'ŒSTROGÈNES HÉTÉROCYCLIQUES ET LEURS UTILISATIONS
  申请人：HOFFMANN LA ROCHE

  公开号：WO2016189011A1

  公开（公告）日：2016-12-01

  Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

  本发明描述了作为雌激素受体调节剂的化合物。同时，还描述了包含本发明所述化合物的药物组合物和药剂，以及使用这种雌激素受体调节剂的方法，包括单独使用和与其他化合物联合使用，用于治疗由雌激素受体介导或依赖的疾病或状况。
• [EN] 6-AMINO-2-PHENYLAMINO-1H-BENZIMIDAZOLE-5-CARBOXAMIDE- DERIVATIVES AND THEIR USE AS MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1 INHIBITORS<br/>[FR] DÉRIVÉS DE 6 -AMINO- 2 - PHÉNYLAMINO- 1H-BENZIMIDAZOLE- 5 -CARBOXAMIDE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA PROSTAGLANDINE E2 SYNTHASE-1 MICROSOMALE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012076673A1

  公开（公告）日：2012-06-14

  This invention relates to compounds of formula (I) their use as inhibitors of the microsomal prostaglandin E2 synthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions. A, L, M, W, R1, R2, R3, R4, R6, R7, R9, Ra, Rb have meanings given in the description.

  这项发明涉及式(I)的化合物，它们作为微粒体前列腺素E2合酶-1(mPGES-1)的抑制剂的用途，含有它们的药物组合物，以及它们作为治疗和/或预防炎症性疾病和相关症状的药物的用途。A、L、M、W、R1、R2、R3、R4、R6、R7、R9、Ra、Rb在描述中有给定的含义。